Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say

Halozyme Therapeutics (HALO) reported $298.01 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 29.6%. EPS of $1.26 for the same period compares to $0.82 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $284.02 million, representing a surprise of +4.93%. The company delivered an EPS surprise of +8.62%, with the consensus EPS estimate being $1.16.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Halozyme Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Product sales, net: $79.36 million compared to the $75.16 million average estimate based on six analysts. The reported number represents a change of -0.3% year over year. Revenues- Royalties: $170.42 million versus $159.68 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +39.6% change. Revenues- Revenues under collaboration agreements: $48.23 million compared to the $49.20 million average estimate based on six analysts. The reported number represents a change of +69.9% year over year. View all Key Company Metrics for Halozyme Therapeutics here>>>Shares of Halozyme Therapeutics have returned +6.4% over the past month versus the Zacks S&P 500 composite's +4.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks